[go: up one dir, main page]

NI200500174A - Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias - Google Patents

Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias

Info

Publication number
NI200500174A
NI200500174A NI200500174A NI200500174A NI200500174A NI 200500174 A NI200500174 A NI 200500174A NI 200500174 A NI200500174 A NI 200500174A NI 200500174 A NI200500174 A NI 200500174A NI 200500174 A NI200500174 A NI 200500174A
Authority
NI
Nicaragua
Prior art keywords
useful
inflammatory diseases
beta
carboniles
treatment
Prior art date
Application number
NI200500174A
Other languages
English (en)
Inventor
Michael E Hepperle
Julie Fields Liu
Francois Soucy
Yingchun Ye
Robert S Murray
Raman Prakash
Jeremy D Little
Alfredo Castro
Hormoz Mazdiyasni
Paul E Fleming
Dominic Rynolds
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NI200500174A publication Critical patent/NI200500174A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención propociona compuestos beta-carbolina de fórmula (I): donde el anillo A es un anillo piridinilo, pirimidinilo,morfolinilo, piperidinilo,piperazinilo, pirrolidinilo, piranilo, tetrahidrofuranoilo,ciclohexilo, ciclopentilo, o tiomorfolinilo sustituido y R1, R2 y R3 son como se han definido en la memoria descriptiva. Los compuestos son inhibidores de IKK-2, que son útiles para tratar enfermedades mediadas por IKK-2 tales como enfermedades inflamatorias y cáncer.
NI200500174A 2003-04-09 2005-10-07 Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias NI200500174A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09

Publications (1)

Publication Number Publication Date
NI200500174A true NI200500174A (es) 2006-04-17

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200500174A NI200500174A (es) 2003-04-09 2005-10-07 Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias

Country Status (22)

Country Link
US (2) US7727985B2 (es)
EP (1) EP1611134A1 (es)
JP (1) JP2006522824A (es)
KR (1) KR20060006031A (es)
CN (1) CN1802375A (es)
AU (1) AU2004230952A1 (es)
BR (1) BRPI0409263A (es)
CA (1) CA2521300A1 (es)
CO (1) CO5700746A2 (es)
CR (1) CR8042A (es)
EA (1) EA009121B1 (es)
EC (1) ECSP056145A (es)
HR (1) HRP20050926A2 (es)
MA (1) MA27837A1 (es)
MX (1) MXPA05010793A (es)
NI (1) NI200500174A (es)
NO (1) NO20054598L (es)
OA (1) OA13115A (es)
RS (1) RS20050832A (es)
TN (1) TNSN05257A1 (es)
WO (1) WO2004092167A1 (es)
ZA (1) ZA200508198B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1802375A (zh) 2003-04-09 2006-07-12 千禧药品公司 用于治疗炎性疾病的β－咔啉
WO2005111037A1 (en) * 2004-04-09 2005-11-24 Millennium Pharmaceuticals, Inc. Beta-carbolines useful for treating inflammatory disease
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007061764A2 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
CA2646316C (en) 2006-03-15 2016-05-24 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
BRPI0720032A2 (pt) * 2006-12-13 2013-12-17 Gilead Sciences Inc Composto e sais farmaceuticamente aceitáveis dos mesmos, processo, formulação de aerossol, método para a prevenção e tratamento de inflamação pulmonar ou broncoconstrição, e, uso de um composto.
WO2009054970A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Mesylate salt of an ikk inhibitor
WO2009054965A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Salts of n- (6-chloro-9h-pyrido [3,4-b] ind0l-8-yl) -4- [2- (2, 6-dimethyl-4-morpholinyl) -2-0x0e thyl] -6, 6-dimethyl-morpholinecarboxamide
JP5892791B2 (ja) 2008-05-14 2016-03-23 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 適応免疫における免疫調節物質の効果をモニターするための方法およびキット
WO2010038465A1 (ja) 2008-10-02 2010-04-08 旭化成ファーマ株式会社 ８位置換イソキノリン誘導体及びその用途
MX2012011341A (es) 2010-03-30 2012-11-12 Novartis Ag Inhibidores de pkc para el tratamiento de linfoma de celulas-b que tenga señalizacion activa cronica de receptores de celulas-b.
JP6049216B2 (ja) * 2011-03-28 2016-12-21 エスジェイティー モレキュラー リサーチ，エス．エル． メタボリック症候群の処置のための化合物
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104412B1 (en) * 1998-08-12 2005-06-15 Pfizer Products Inc. Tace inhibitors
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
EP1268477B1 (en) * 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
ATE465161T1 (de) * 2000-03-15 2010-05-15 Sanofi Aventis Deutschland Substituierte beta-carboline mit ikb-kinase hemmender wirkung
EP1427706B1 (en) 2001-09-19 2007-05-30 Pharmacia Corporation Substituted pyrazolo compounds for the treatment of inflammation
DE60217532T8 (de) * 2001-11-07 2008-02-07 Millennium Pharmaceuticals, Inc., Cambridge Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas
DE602004016127D1 (de) * 2003-03-07 2008-10-09 Lilly Co Eli Antagonisten der opioidrezeptoren
CN1802375A (zh) 2003-04-09 2006-07-12 千禧药品公司 用于治疗炎性疾病的β－咔啉

Also Published As

Publication number Publication date
BRPI0409263A (pt) 2006-03-28
CR8042A (es) 2006-05-30
US7727985B2 (en) 2010-06-01
ZA200508198B (en) 2007-01-31
EA200501584A1 (ru) 2006-06-30
EA009121B1 (ru) 2007-10-26
HRP20050926A2 (en) 2006-06-30
JP2006522824A (ja) 2006-10-05
NO20054598D0 (no) 2005-10-06
US20040235839A1 (en) 2004-11-25
US20100093713A1 (en) 2010-04-15
NO20054598L (no) 2005-10-27
AU2004230952A1 (en) 2004-10-28
RS20050832A (sr) 2007-12-31
MA27837A1 (fr) 2006-04-03
WO2004092167A8 (en) 2006-01-05
EP1611134A1 (en) 2006-01-04
TNSN05257A1 (en) 2007-07-10
CN1802375A (zh) 2006-07-12
KR20060006031A (ko) 2006-01-18
OA13115A (en) 2006-11-10
CA2521300A1 (en) 2004-10-28
ECSP056145A (es) 2006-04-19
WO2004092167A1 (en) 2004-10-28
MXPA05010793A (es) 2005-12-05
CO5700746A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
NI200500174A (es) Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
UY28333A1 (es) Inhibidores de caspasa y sus usos.
CO6870032A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
CR8410A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
DE602005025803D1 (de) Stereoisomerisch angereicherte 3-aminocarbonyl-bicyclohepten-pyrimidindiamin-verbindungen und ihre verwendungen
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
MY142988A (en) Novel aminobenzophenone compounds
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
EA201170344A1 (ru) Азаиндольные ингибиторы iap
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2023002362A1 (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
UY29074A1 (es) Heterocíclicos fusionados seleccionados y usos de los mismos
PE20150348A1 (es) Compuestos de azetidina y piperidina utiles como inhibidores de pde10
SV2006001934A (es) Derivados de morfolina como inhibidores de la recaptacion de norepinefrina ref. x-15830
DK1687301T3 (da) Thiaepothilone til behandling af kræftsygdomme